article Open AccessTop 1% cited

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Antimicrobial Agents and Chemotherapy · 2020 · Vol. 64(7)

Sangeun Jeon✉(Institut Pasteur Korea)Meehyun Ko(Institut Pasteur Korea)Jihye Lee(Institut Pasteur Korea)Inhee Choi(Institut Pasteur Korea)Soo Young Byun(Institut Pasteur Korea)Soonju Park(Institut Pasteur Korea)David Shum(Institut Pasteur Korea)Seungtaek Kim(Institut Pasteur Korea)

View via DOI Publisher page

Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC<sub>50</sub>s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies Influenza Virus Research StudiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)VirologyMedicinePharmacologyDrug approvalAntiviral drugIdentification (biology)

MeSH terms

BetacoronavirusCOVID-19SARS-CoV-2AnimalsAnti-Inflammatory AgentsAntiviral AgentsCell LineChlorocebus aethiopsDrug Evaluation, PreclinicalHumansNiclosamidePneumonia, ViralPregnenedionesVero CellsCoronavirus Infections